Zentalis Pharmaceuticals, Inc. (ZNTL)

12.96 +0.68 (+5.54%) At close: 04:00PM EST

Zentalis Pharmaceuticals, Inc.

1359 Broadway
Suite 1710
New York, NY 10018
United States
212 433 3791
https://zentalis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 156

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Kimberly Lynn Blackwell M.D.	CEO & Director	1.12M	N/A	1969
Mr. Cameron S. Gallagher M.B.A.	Co-Founder, President & Director	767.69k	N/A	1970
Ms. Melissa B. Epperly M.B.A.	CFO & Treasurer	721.64k	N/A	1978
Ms. Andrea Paul J.D.	General Counsel & Corporate Secretary	668.2k	N/A	1981
Dr. Carrie Brownstein M.D.	Chief Medical Officer	755.06k	N/A	1970
Dr. Mark Lackner Ph.D.	Chief Translational Officer & Head of Biomarker Strategy and Chief Scientific Officer	N/A	N/A	1967
Ms. Kimberly Freeman	Chief Strategy Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Corporate governance

Zentalis Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.